Society for Translational Oncology Fellows’ Forum (STOFF)

 

Society for Translational Oncology Fellows' Forum (STOFF) was an intensive 3-day workshop that occurred Thursday, August 18 - Saturday, August 20, 2022, bringing together 25 fellows and junior faculty within 5 years of training completion from leading medical, surgical, radiation, and pediatric oncology groups and subspecialty fellowships to educate these rising stars on issues around and barriers to successful translational cancer research.

STOFF Class of 2022

Congratulations to our 2022 Fellows

Our Fellows | Our Faculty | Agenda

 

This forum is internationally acclaimed for its focused, practical, and personal approach. It provides guidance to oncology fellows and junior faculty regarding how to apply translational research findings in tumor biology to improve patient outcomes. The broad-based curriculum covers a range of topics related to new drug development.

A special thank you to the 2022 STOFF co-chairs Dr. Keith Flaherty (Massachusetts General Hospital/Harvard Medical School), Dr. Ross Levine (Memorial Sloan Kettering Cancer Center), and Dr. Stacey Berg (Baylor College of Medicine/Texas Children’s Cancer Center) for their leadership and direction.


STO gratefully acknowledges support from:
Amgen, Inc.
Chugai Foundation for Innovative Drug Discovery Science
Farallon Capital Management, L.L.C.
Loxo@Lilly

Selected Fellow Summaries of 2022 STOFF Presentations


Click on each speaker to read the presentation summary.

PI Role and Conflict of Interest
 

Stacey Berg, MD
Texas Children’s Cancer Center
Houston, Texas

 

 

Career Development in Academia
 
 
 

Bernardo Goulart, MD, MS
US Food and Drug Administration
Silver Spring, Maryland

 

 

Oncology Drug Development: A Regulatory Perspective

Tatiana Prowell, MD
US Food and Drug Administration
Silver Spring, Maryland

 

 

Chabner

 Working with Industry in Drug Development

Bruce A. Chabner, MD
Massachusetts General Hospital
Cancer Center
Boston, Massachusetts

 

Issues in Design of Translational Research Trials
 
 

Susan Hilsenbeck, PhD
Baylor College of Medicine
Houston, Texas

 

 

Reynolds

Systemic Toxicity Associated With Immune Checkpoint Inhibitors

Kerry Reynolds, MD
Massachusetts General Hospital
Cancer Center
Boston, Massachusetts

 

Corcoran

Science at the Interface Between the Lab and the Clinic

Ryan Corcoran, MD, PhD
Massachusetts General Hospital
Cancer Center
Boston, Massachusetts

 

Therapeutic Resistance Including Serial Biopsy, Rapid Autopsy and Blood-based Biomarkers Platforms

Dejan Juric, MD
Massachusetts General Hospital
Cancer Center
Boston, Massachusetts

 

New Drug Development in 2022: Progress, Challenges, and Prices

Thomas Roberts, MD, MSocSci
Farallon Capital Management
San Francisco, California

 

 

Phase I/II Clinical Trials: Protocol Development/Hypothesis Testing

Keith Flaherty, MD
Massachusetts General Hospital
Cancer Center
Boston, Massachusetts

 

Immune Checkpoint Inhibition in Advanced Cancer
 
 

Michael Postow, MD
Memorial Sloan Kettering Cancer Center
New York, New York

 

 

STOFF 2024 Button


Privacy Policy | Terms of Use | Contact Us

Society for Translational Oncology (STO) is a 501(c)(3) not-for-profit organization.